Issue Date: April 14, 2014
Daiichi Quits On Ranbaxy
A little more than five years after acquiring a majority stake in Ranbaxy Laboratories, Japan’s Daiichi Sankyo is throwing in the towel on the troubled Indian firm. Sun Pharmaceutical Industries, one of India’s largest manufacturers of generic drugs, will acquire Ranbaxy for about $4.0 billion.
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society